ライフサイエンスコーパス: antineoplastic agent

1 ted apoptosis by etoposide, a representative antineoplastic agent.

2 e II diabetes that has gained interest as an antineoplastic agent.

3 to improve the therapeutic efficacy of this antineoplastic agent.

4 oing Phase I clinical testing as a potential antineoplastic agent.

5 )F-FLT) in assessing its effectiveness as an antineoplastic agent.

6 rent clinical assessment of clioquinol as an antineoplastic agent.

7 n attractive candidate for development as an antineoplastic agent.

8 hibitor developed specifically for use as an antineoplastic agent.

9 door for clinical trials evaluating it as an antineoplastic agent.

10 linical information on gallium nitrate as an antineoplastic agent.

11 of IAP proteins can modulate the efficacy of antineoplastic agents.

12 ificantly increases the efficacy of existing antineoplastic agents.

13 ts that can be mitigated by encapsulation of antineoplastic agents.

14 plausible pharmacological strategy for novel antineoplastic agents.

15 e viable resources in the development of new antineoplastic agents.

16 ases as novel targets for the development of antineoplastic agents.

17 olecules targeting translation initiation as antineoplastic agents.

18 ramifications for the use of these drugs as antineoplastic agents.

19 ications of these findings for resistance to antineoplastic agents.

20 nts may have applicability as biotherapeutic antineoplastic agents.

21 signal transduction modulators as potential antineoplastic agents.

22 the development of new immunosuppressive and antineoplastic agents.

23 multiple oncoproteins may lead to effective antineoplastic agents.

24 proach for the development of new classes of antineoplastic agents.

25 e for the development of cdk2 antagonists as antineoplastic agents.

26 n cancer patients who receive these drugs as antineoplastic agents.

27 ellular targets of many structurally diverse antineoplastic agents.

28 ramide in the lethal actions of conventional antineoplastic agents.

29 on may contribute to NF-kappaB activation by antineoplastic agents.

30 ifaceted approach for the development of new antineoplastic agents.

31 l sensitivity to this promising new class of antineoplastic agents.

32 form the basis for the development of novel antineoplastic agents.

33 timal combinations of these drugs with other antineoplastic agents.

34 as mapped with respect to several classes of antineoplastic agents.

35 nique intracellular and selective target for antineoplastic agents.

36 asing their susceptibility to cycle-specific antineoplastic agents.

37 to improve performance and safety of current antineoplastic agents.

38 for designing biocompatible target specific antineoplastic agents.

39 described possible activity of quinolones as antineoplastic agents.

40 lation to cytotoxic chemotherapy or targeted antineoplastic agents.

41 iatric patients who receive high-emetic-risk antineoplastic agents.

42 resistance to paclitaxel and possibly other antineoplastic agents.

43 entify complex III as a potential target for antineoplastic agents.

44 e proposal that these ligands may be used as antineoplastic agents.

45 reast cancer cells to cytoskeletal targeting antineoplastic agents.

46 tients who are treated with high emetic risk antineoplastic agents.

47 logic utility as angiogenesis inhibitors and antineoplastic agents.

48 by current or previous treatment with other antineoplastic agents.

49 hione conjugates and several natural product antineoplastic agents.

50 ed for cancer cell apoptosis induced by many antineoplastic agents.

51 metabolism and may be a suitable target for antineoplastic agents.

52 a group, are unresponsive to treatment with antineoplastic agents.

53 l scaffold to improve the design of specific antineoplastic agents.

54 logic-based therapies are being developed as antineoplastic agents.

55 the tumor-specific activity of DNA-damaging antineoplastic agents.

56 In this study, we examined whether antineoplastic agents 5-fluorouracil (5-FU) and dacarbaz

57 b, alone or in combination with the standard antineoplastic agents, 5-fluoruracil or irinotecan.

58 n of cellular apoptotic responses to various antineoplastic agents, a laser-based technology, Optopho

59 tide or FK228) is a member of a new class of antineoplastic agents active in T-cell lymphoma, the his

60 bacterial, fungal, and parasitic infections, antineoplastic agents against cancer cells, and perturba

61 n continue to be treated with this important antineoplastic agent and how such retreatment might be u

62 city that are reported to be associated with antineoplastic agents and discuss their putative mechani

63 ic investigation of PPARdelta antagonists as antineoplastic agents and implicate altered PPARdelta-cy

64 t from mechanisms used by some DNA-damaging, antineoplastic agents and other apoptotic stimuli.

65 5'Bcl-x AS sensitized cells to several antineoplastic agents and radiation and was effective in

66 , for a 1-year period, suffered reactions to antineoplastic agents and were referred to the Desensiti

67 kers has revealed many potential targets for antineoplastic agents, and a particularly important aber

68 argeting of these immunosuppressive cells by antineoplastic agents, and consider current challenges a

69 in C given before mechanistically dissimilar antineoplastic agents antagonizes therapeutic efficacy i

70 Taxane antineoplastic agents are extensively taken up into hepa

71 Importantly, most clinically useful antineoplastic agents are less potent and efficacious in

72 or in combination with gemcitabine and other antineoplastic agents are warranted.

73 -870,893 alone and in combination with other antineoplastic agents are warranted.

74 o asparaginyl residues and that DNA-damaging antineoplastic agents as well as other stimuli can incre

75 The antineoplastic agent benzyl isothiocyanate (BITC) acts b

76 f advanced-stage NSCLC and were treated with antineoplastic agents between 2000 and 2011 (N = 22,163)

77 otic enzyme that inactivates the widely used antineoplastic agent bleomycin (BLM) and is a primary ca

78 The antineoplastic agent bryostatin-1 (bryo-1) possesses pow

79 was combined with seven of the eight tested antineoplastic agents but was highly dependent upon admi

80 Doxorubicin is a highly effective antineoplastic agent, but it can produce the serious sid

81 pathy is a dose-limiting side effect of many antineoplastic agents, but the mechanisms underlying the

82 ate the response of an individual's tumor to antineoplastic agents, but these tumor fragments are cul

83 ion can affect the sensitivity of cancers to antineoplastic agents by altering expression of genes cr

84 This antineoplastic agent can be delivered effectively by bot

85 These highly active antineoplastic agents can be used for incorporation into

86 e induction of a senescent-like phenotype by antineoplastic agents can contribute therapeutic efficac

87 ce or its displacement from the chromatin by antineoplastic agents caused an increase in the levels o

88 sis included young age and chemotherapy with antineoplastic agents, cefotaxime, vancomycin, and cefta

89 clude the aminoglycoside antibiotics and the antineoplastic agent cisplatin.

90 The present SAR studies of the antineoplastic agent combretastatin A-4 (1c) were focuse

91 Hydroxyurea is an antineoplastic agent commonly used to treat myeloprolife

92 sed in the present study for delivery of the antineoplastic agent daunomycin to the rat brain.

93 Imatinib, an antineoplastic agent, demonstrated antiinflammatory and

94 , CREB, SP-1, or TFIID were not activated by antineoplastic agents demonstrating specificity of NF-ka

95 ast, docetaxel (Taxotere), a closely related antineoplastic agent, did not activate SXR and displayed

96 novel procedure to couple enzymatically the antineoplastic agent doxorubicin (Dox) on the galactose

97 rs and is suppressed in cardiac cells by the antineoplastic agent doxorubicin.

98 n vitro and in vivo tumor sensitivity to the antineoplastic agent doxorubicin.

99 xel (Taxol) is a potent and highly effective antineoplastic agent for the treatment of advanced, drug

100 our data, bortezomib represents a promising antineoplastic agent for the treatment of ATC.

101 port the clinical development of CV890 as an antineoplastic agent for the treatment of localized or m

102 Currently, FTIs are being explored as antineoplastic agents for the treatment of several malig

103 structurally diverse hydrophobic amphipathic antineoplastic agents from cells, with different mechani

104 The use of interleukin 2 (IL-2) as an antineoplastic agent has been limited by the serious tox

105 Docetaxel is a highly active antineoplastic agent; however, grade IV leukopenia occur

106 activity of multiple widely used classes of antineoplastic agents, human cancer cell lines were trea

107 , a PP2A inhibitor which has been used as an antineoplastic agent in clinical trials, is also able to

108 th RXR-selective ligand may thus be a useful antineoplastic agent in differentiation induction therap

109 275) has been identified recently as a novel antineoplastic agent in the primary screen conducted by

110 IFN-alpha is an antineoplastic agent in the treatment of several solid a

111 e inhibitor to undergo clinical trials as an antineoplastic agent in the United States, has attracted

112 orubicin (DOXO) is one of the most effective antineoplastic agents in clinical practice.

113 from combining flavopiridol with eight other antineoplastic agents in four different administration s

114 d consider how to combine antiretroviral and antineoplastic agents in patients with HIV who are recei

115 timal dose for use in combination with other antineoplastic agents in pediatric patients.

116 ggest that As(2)O(3) and AA may be effective antineoplastic agents in refractory MM and that AA might

117 Approximately 44% of patients received antineoplastic agents in the last 30 days of life throug

118 d in B cell lymphomas by anti-Fas or various antineoplastic agents in the presence and absence of FDC

119 ng term antiproliferative effects of diverse antineoplastic agents including paclitaxel, etoposide, 7

120 d resistant (MCF-7/Adr-, T47D, and SKBr3) to antineoplastic agents, incubation with the sigma-2 subty

121 The demonstration that many antineoplastic agents induce apoptosis in susceptible ce

122 paullones, a dual property observed in other antineoplastic agents influencing phosphoester transfer.

123 Desensitization to antineoplastic agents is becoming a standard of care.

124 The therapeutic value of DNA-damaging antineoplastic agents is dependent upon their ability to

125 -The clinical efficacy of anthracycline antineoplastic agents is limited by a high incidence of

126 The clinical utility of antineoplastic agents is limited by the development of d

127 inical use of doxorubicin, widely used as an antineoplastic agent, is markedly hampered by severe car

128 ed the sensitivity of these cells to several antineoplastic agents known to be cell cycle-dependent o

129 tial for increased exposure of the tumour to antineoplastic agents leading to improved cytotoxicity.

130 Antineoplastic agents loaded on 50-100-microm microspher

131 the side effects of cisplatin, a widely used antineoplastic agent, major efforts have been made to de

132 storically, it has been well recognized that antineoplastic agents may have adverse effects on multip

133 idoreductase 1 (NQO1) on the activity of the antineoplastic agent mitomycin C (MC) under aerobic and

134 as osteosarcoma, for preclinical testing of antineoplastic agents offers significant advantages over

135 xic effect of ET-743 combined with six other antineoplastic agents on human breast cancer cell lines,

136 ated the effect of bryostatin-1 (Bryo-1), an antineoplastic agent, on dendritic cell (DC) maturation,

137 antiemetic regimens that are appropriate for antineoplastic agents or radiotherapy being administered

138 mens for adults who receive high-emetic-risk antineoplastic agents or who experience breakthrough nau

139 apeutic tool for hypersensitivity to several antineoplastic agents (oxaliplatin, carboplatin, paclita

140 The antineoplastic agent paclitaxel (TaxolTM), a microtubule

141 consist of topo I-targeting agents and other antineoplastic agents, particularly DNA-damaging agents.

142 The performance and safety of current antineoplastic agents, particularly water-insoluble drug

143 ne compound previously used clinically as an antineoplastic agent potentiates the presynaptic functio

144 edules and combining temozolomide with other antineoplastic agents, radiation therapy, or drug resist

145 Targeted antineoplastic agents show great promise in the treatmen

146 menting the transvascular delivery of larger antineoplastic agents such as gene targeting vectors and

147 F ablation augments the delivery of systemic antineoplastic agents such as liposomal doxorubicin.

148 The common use of antineoplastic agents such as mitomycin C, doxorubicin,

149 We also found that ET-743, a potent antineoplastic agent, suppressed MDR1 transcription by a

150 Pharmacological traits of the antineoplastic agent taxol may originate in part from it

151 All antineoplastic agents tested caused mitochondrial membra

152 nd colony formation after treatment with all antineoplastic agents tested.

153 TAS-103 is a novel antineoplastic agent that is active against in vivo tumo

154 Bortezomib (PS-341) is a novel antineoplastic agent that is well tolerated at doses not

155 Bryostatin-1, a macrocyclic lactone, is an antineoplastic agent that potently activates protein kin

156 Cisplatin is a commonly used antineoplastic agent that produces ototoxicity that is m

157 tment with paclitaxel (trade name Taxol), an antineoplastic agent that stabilizes cellular microtubul

158 Paclitaxel, an antineoplastic agent that stabilizes microtubules and ar

159 raf-1 kinase may be of considerable value as antineoplastic agents that display activity against a wi

160 In contrast to most other antineoplastic agents that generate reactive oxygen spec

161 Vinca alkaloids are antineoplastic agents that halt cell division at metapha

162 thesis that flavopiridol, like several other antineoplastic agents that kill noncycling cells, might

163 at can enhance the efficacy of biguanides as antineoplastic agents that target cancer cell energy met

164 rease in apoptosis in cells treated with the antineoplastic agents that was not due to up-regulation

165 n deazapurines as antibiotic, antiviral, and antineoplastic agents, the biosynthetic route toward dea

166 ew the development of successful preclinical antineoplastic agents, their associated limitations, and

167 zymatically mediated, glycosidic coupling of antineoplastic agents to antibodies specific for tumor-a

168 might be useful in targeting the delivery of antineoplastic agents to such cancers.

169 Paclitaxel (Taxol) is a frontline antineoplastic agent used to treat a variety of solid tu

170 of the interaction between ET-743 and other antineoplastic agents using the combination index method

171 pressing) and MCJ-transfected OV167 cells to antineoplastic agents was evaluated.

172 a desensitization to cell cycle-independent antineoplastic agents was found in the cells arrested by

173 increased resistance to cell cycle-dependent antineoplastic agents was found in the cells when the ex

174 apy, 51 candidate genes from the pathways of antineoplastic agents were resequenced to identify commo

175 concentrations, enhanced the effects of both antineoplastic agents when used in combination.

176 Adriamycin is a popular antineoplastic agent whose ability to form covalent addu

177 is likely that interest in CDK inhibitors as antineoplastic agents will continue for the foreseeable

178 Deoxynyboquinone (DNQ) is a potent antineoplastic agent with an unknown mechanism of action